Velpatasvir, also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays. GS-5816 demonstrated pangenotypic antiviral activity in patients with genotype 1-4 HCV infection. It will be further evaluated in combination with other pangenotypic direct-acting antivirals to achieve the goal of developing a well-tolerated, highly effective treatment for all HCV genotypes.
HCV Protease Inhibitors Related Prodcuts:
Daclatasvir; Daclatasvir hcl; Telaprevir; Lomibuvir; Danoprevir; Paritaprevir; Paritaprevir dihydrate; Grazoprevir; Elbasvir; Ombitasvir; Simeprevir; Ledipasvir; Boceprevir